Exhibit 99.1
| Media Contact: | Investor Contact: | |
| Eliza Schleifstein | Greg S. Lea | |
| Argot Partners | Chief Financial Officer | |
| (917) 763-8106 | EnteroMedics Inc. | |
| eliza@argotpartners.com | (651) 634-3003 | |
| glea@enteromedics.com |
EnteroMedics Announces Appointment of Dan Gladney as Chairman of the Board of Directors
ST. PAUL, Minnesota, September 27, 2016 – EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the appointment of President and Chief Executive Officer Dan Gladney as Chairman of the Board of Directors, effective October 14, 2016. Mr. Gladney will succeed Dr. Mark Knudson, co-founder of EnteroMedics, who will be retiring from the Board. Dr. Knudson will be Special Advisor to the CEO on clinical and scientific activities following his retirement. As part of this transition, the EnteroMedics Board will take action at its December meeting to create an Independent Lead Director position and has asked the Nominating and Governance Committee to recommend a candidate for appointment to that position.
“It is an honor to lead the EnteroMedics Board of Directors at such a pivotal time for the company,” said Mr. Gladney. “EnteroMedics’ commitment to combatting morbid obesity only gets stronger as we press onward towards our goals of both obtaining broad reimbursement coverage for vBloc Therapy® and ensuring that this proven option is as widely available as possible. I would like to thank Mark for his service and dedication to the company over the last 14 plus years.”
“Dan is a highly capable, effective executive with a proven track record of success at EnteroMedics,” said Dr. Knudson. “It has been a privilege to lead the EnteroMedics’ Board of Directors, and knowing that Dan will be taking over leaves me confident that the company will maintain its dominant position in the neuromodulation device industry in the areas of obesity, diabetes and gastrointestinal disorders.”
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by a pacemaker-like device called the vBloc® System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics’ vBloc® System has received U.S. Food and Drug Administration approval and CE Mark.
Information about the vBloc® System and vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the vBloc System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc Therapy and vBloc System. For additional prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to regain and then maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc® System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc® System; physician adoption of our vBloc® System and vBloc® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the annual report on Form 10-K filed March 28, 2016. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.